Literature DB >> 16273651

Expression of serine protease SNC19/matriptase and its inhibitor hepatocyte growth factor activator inhibitor type 1 in normal and malignant tissues of gastrointestinal tract.

Lei Zeng1, Jiang Cao, Xing Zhang.   

Abstract

AIM: To provide the expression profile of serine protease SNC19/matriptase and its inhibitor hepatocyte growth factor activator inhibitor type 1 (HAI-1) in normal and malignant tissues of gastrointestinal tract at mRNA level for further study on their correlations with tumor progression and metastasis.
METHODS: Total RNAs were prepared from 37 samples of colorectal cancer tissues, 40 samples of gastric cancer tissues, and their adjacent normal tissues. The expression of SNC19/matriptase and HAI-1 in these samples was detected by real-time fluorescent quantitative PCR using glyceraldehyde-3-phosphate dehydrogenase as internal standard, and the clinical significance for the correlation with clinicopathological parameters was evaluated.
RESULTS: In gastric cancer tissues the expression of HAI-1 and SNC19/matriptase was significantly lower than that in the corresponding adjacent normal tissues (Z = -3.280, P = 0.006; Z = -4.651, P = 0.000). HAI-1:SNC19/matriptase ratio showed no difference between normal and malignant tissues (P>0.05). Analysis of clinicopathological parameters showed decreased expression of HAI-1 and HAI-1:SNC19/matriptase ratio associated with stage III/IV gastric tumors as compared to stage I/II ones (Z = -2.140, P = 0.031; Z = -2.155, P = 0.031), and with lymph node-positive gastric cancer tissues as compared to lymph node-negative ones (Z = -2.081, P = 0.036; Z = -2.686, P = 0.006). The expression of SNC19/matriptase had no relationship with stages and lymph node metastasis (P>0.05). The expression of HAI-1 and HAI-1:SNC19/matriptase ratio increased in well-differentiated gastric cancer tissues, but there was no statistical significance (P>0.05). The difference of SNC19/matriptase expression was not significant in gastric cancer tissues of different histological differentiation status (P>0.05). In colorectal cancer tissues, the expression of HAI-1 and SNC19/matriptase was also markedly lower than that in their adjacent normal tissues (Z = -3.100, P = 0.002; Z = -2.731, P = 0.006), whereas HAI-1:SNC19/matriptase ratio showed no difference. Decreased expression of HAI-1 was associated with increased invasive depth and lymph node metastasis, but there was no statistical significance (P>0.05). The difference of SNC19/matriptase expression and HAI-1:SNC19/matriptase ratio was not significant in different stages and different lymph node metastasis status (P>0.05). The expression of SNC19/matriptase, HAI-1 or HAI-1:SNC19/martiptase ratio showed no difference in colorectal cancer tissues of different histological differentiation status (P>0.05).
CONCLUSION: The expressions of SNC19/matriptase and its inhibitor HAI-1 are decreased in gastrointestinal cancer tissues compared to their normal counterparts, and the decreased expression of HAI-1 may correlate with invasion and lymph node metastasis. The possible mechanisms involved need to be further investigated.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16273651      PMCID: PMC4436641          DOI: 10.3748/wjg.v11.i39.6202

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  33 in total

1.  The activation of matriptase requires its noncatalytic domains, serine protease domain, and its cognate inhibitor.

Authors:  Michael D Oberst; Cicely A Williams; Robert B Dickson; Michael D Johnson; Chen-Yong Lin
Journal:  J Biol Chem       Date:  2003-05-08       Impact factor: 5.157

Review 2.  Possible role of matriptase in the diagnosis of ovarian cancer.

Authors:  Michael D Johnson; Michael D Oberst; Chen-Yong Lin; Robert B Dickson
Journal:  Expert Rev Mol Diagn       Date:  2003-05       Impact factor: 5.225

3.  Functional characterization of Kunitz domains in hepatocyte growth factor activator inhibitor type 1.

Authors:  Kimitoshi Denda; Takeshi Shimomura; Toshiya Kawaguchi; Keiji Miyazawa; Naomi Kitamura
Journal:  J Biol Chem       Date:  2002-01-22       Impact factor: 5.157

4.  Characterization of colorectal-cancer-related cDNA clones obtained by subtractive hybridization screening.

Authors:  J Cao; X Cai; L Zheng; L Geng; Z Shi; C C Pao; S Zheng
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

5.  A novel serine protease SNC19 associated with human colorectal cancer.

Authors:  J Cao; S Zheng; L Zheng; X Cai; Y Zhang; L Geng; Y Fang
Journal:  Chin Med J (Engl)       Date:  2001-07       Impact factor: 2.628

6.  Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters.

Authors:  Michael D Oberst; Michael D Johnson; Robert B Dickson; Chen-Yong Lin; Baljit Singh; Moira Stewart; Alastair Williams; Awatif al-Nafussi; John F Smyth; Hani Gabra; Grant C Sellar
Journal:  Clin Cancer Res       Date:  2002-04       Impact factor: 12.531

7.  Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer.

Authors:  Jung Y Kang; Marisa Dolled-Filhart; Idris Tolgay Ocal; Baljit Singh; Chen-Yong Lin; Robert B Dickson; David L Rimm; Robert L Camp
Journal:  Cancer Res       Date:  2003-03-01       Impact factor: 12.701

8.  Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA.

Authors:  W M Mars; R Zarnegar; G K Michalopoulos
Journal:  Am J Pathol       Date:  1993-09       Impact factor: 4.307

9.  The hepatocyte growth factor regulatory factors in human breast cancer.

Authors:  Christian Parr; Gareth Watkins; Robert E Mansel; Wen G Jiang
Journal:  Clin Cancer Res       Date:  2004-01-01       Impact factor: 12.531

10.  Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor.

Authors:  L Naldini; K M Weidner; E Vigna; G Gaudino; A Bardelli; C Ponzetto; R P Narsimhan; G Hartmann; R Zarnegar; G K Michalopoulos
Journal:  EMBO J       Date:  1991-10       Impact factor: 11.598

View more
  23 in total

1.  A novel signaling axis of matriptase/PDGF-D/ß-PDGFR in human prostate cancer.

Authors:  Carolyn V Ustach; Wei Huang; M Katie Conley-LaComb; Chen-Yong Lin; Mingxin Che; Judith Abrams; Hyeong-Reh Choi Kim
Journal:  Cancer Res       Date:  2010-11-23       Impact factor: 12.701

2.  Design and Synthesis of Nonpeptide Inhibitors of Hepatocyte Growth Factor Activation.

Authors:  Phanindra K M Venukadasula; Benjamin Y Owusu; Namita Bansal; Larry J Ross; Judith V Hobrath; Donghui Bao; Jackie W Truss; Murray Stackhouse; Troy E Messick; Lidija Klampfer; Robert A Galemmo
Journal:  ACS Med Chem Lett       Date:  2015-12-22       Impact factor: 4.345

3.  Platelet-derived growth factor-C (PDGF-C) activation by serine proteases: implications for breast cancer progression.

Authors:  Newton J Hurst; Abdo J Najy; Carolyn V Ustach; Lisa Movilla; Hyeong-Reh Choi Kim
Journal:  Biochem J       Date:  2012-02-01       Impact factor: 3.857

4.  Identification of the matriptase second CUB domain as the secondary site for interaction with hepatocyte growth factor activator inhibitor type-1.

Authors:  Kuniyo Inouye; Satoshi Tsuzuki; Makoto Yasumoto; Kenji Kojima; Seiya Mochida; Tohru Fushiki
Journal:  J Biol Chem       Date:  2010-08-03       Impact factor: 5.157

Review 5.  The role of type II transmembrane serine protease-mediated signaling in cancer.

Authors:  Lauren M Tanabe; Karin List
Journal:  FEBS J       Date:  2016-12-24       Impact factor: 5.542

Review 6.  Matriptase: potent proteolysis on the cell surface.

Authors:  Karin List; Thomas H Bugge; Roman Szabo
Journal:  Mol Med       Date:  2006 Jan-Mar       Impact factor: 6.354

7.  Expression and prognostic value of matriptase in ovarian serous adenocarcinoma.

Authors:  Mei Ji; Shunshuang Li; Ya Xie; Zhao Zhao; Weizhong Chang; Yue Li; Xinghan Cheng; Zhuo Wang
Journal:  Oncol Lett       Date:  2017-01-17       Impact factor: 2.967

8.  Engineering a potent inhibitor of matriptase from the natural hepatocyte growth factor activator inhibitor type-1 (HAI-1) protein.

Authors:  Aaron C Mitchell; Deepti Kannan; Sean A Hunter; R Andres Parra Sperberg; Cheryl H Chang; Jennifer R Cochran
Journal:  J Biol Chem       Date:  2018-01-31       Impact factor: 5.157

Review 9.  Type II transmembrane serine proteases as potential targets for cancer therapy.

Authors:  Andrew S Murray; Fausto A Varela; Karin List
Journal:  Biol Chem       Date:  2016-09-01       Impact factor: 3.915

10.  Expression of prostasin and its inhibitors during colorectal cancer carcinogenesis.

Authors:  Joanna Selzer-Plon; Jette Bornholdt; Stine Friis; Hanne C Bisgaard; Inger Mb Lothe; Kjell M Tveit; Elin H Kure; Ulla Vogel; Lotte K Vogel
Journal:  BMC Cancer       Date:  2009-06-25       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.